Petach-Tikva, Israel

Livnat Bangio

USPTO Granted Patents = 7 


 

Average Co-Inventor Count = 4.4

ph-index = 4

Forward Citations = 46(Granted Patents)


Company Filing History:


Years Active: 2011-2019

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Livnat Bangio: Innovator in Glioblastoma Treatment

Introduction

Livnat Bangio is a prominent inventor based in Petach-Tikva, Israel. She has made significant contributions to the field of medical research, particularly in the treatment of glioblastoma, a highly aggressive form of brain cancer. With a total of seven patents to her name, Bangio is recognized for her innovative approaches to cancer therapy.

Latest Patents

Among her latest patents, Bangio has developed compositions and methods for treating glioblastoma (GBM). These methods involve administering a therapeutically effective amount of a viral vector that includes a first polynucleotide sequence encoding a Fas-chimera and a second polynucleotide sequence encoding an endothelial cell-specific promoter. Additionally, she has worked on methods for using a specific anti-angiogenic adenoviral agent, which provides clinical protocols for treating solid tumors using an Ad5-PPE-1-3X-fas-chimera adenovirus vector.

Career Highlights

Bangio's career is marked by her dedication to advancing cancer treatment methodologies. Her work has been instrumental in developing innovative therapeutic strategies that leverage viral vectors to target malignant gliomas effectively.

Collaborations

She collaborates with notable colleagues, including Eyal Breitbart and Dror Harats, who contribute to her research endeavors and the development of her patented technologies.

Conclusion

Livnat Bangio's contributions to glioblastoma treatment exemplify her commitment to innovation in medical research. Her patents reflect a significant advancement in therapeutic approaches, showcasing her role as a leading inventor in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…